Krónikus limfoid leukémia (CLL): vizsgálatok itt: Svájc
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Bellinzona, Bern
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - No phaseTaking peopleStudy of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
- Where
- Aarau, Bellinzona, Bern, Lucerne, Münsterlingen, Neuchâtel, Sankt Gallen, Thun, Winterthur
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- AbbVie
See details and how to joinNCT03342144 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bern, Zurich
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Basel, Bellinzona, Bern, Geneva, Sankt Gallen, Zurich
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - No phaseTaking peopleTransgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Where
- Aarau
- People
- 50 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06357754 - 1. fázisNot yet taking people in SvájcBispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
- Where
- Basel
- Életkor
- 18 év and over
- People
- 12
- Run by
- University Hospital, Basel, Switzerland
See details and how to joinNCT07166549 - 1/2. fázisTaking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Sankt Gallen
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394